



# COA RESEARCH & MANUFACTURING LIMITED COMPANY

P. O. Box DL 1203, Adisadel- Cape Coast GPS Address: CA-1071-5688 0591565778, 0509876891, 0244726611  
www.coarmc.com info@coarmc.com

Our Ref: CRMLC/MDA/VOL.1/23/015.

Your Ref:.....

Date: 28<sup>TH</sup> JULY 2025.....

## FOR IMMEDIATE RELEASE

### COA RESEARCH AND MANUFACTURING LIMITED COMPANY SETS THE RECORD STRAIGHT ON COA-72 CLINICAL TRIALS

The management of **COA Research and Manufacturing Limited Company (COA-RMLC)** wishes to clarify recent media reports regarding the status of COA-72, following a publication in the *Daily Graphic* on Wednesday, 16th July 2025, headlined: ***“COA-72 undergoes clinical trials as anti-HIV drug.”***

This statement is issued to address misinformation contained in the said article and to reaffirm our unwavering commitment to scientific integrity, regulatory compliance, and transparent communication with the public.

#### 1. Clarification on Media Reports

On Monday, 14th July 2025, the Parliamentary Select Committee on Health paid a working visit to COARMLC's facilities. During the visit, management engaged with committee members on the company's ongoing research and development efforts. Unfortunately, the subsequent media reportage by the *Daily Graphic* inaccurately suggested that COA-72 is currently undergoing clinical trials for HIV treatment.

To address this, COARMLC notified Daily Graphic regarding the wrong reportage and a rejoinder was issued, which was published in the *Daily Graphic* on Thursday, 17th July 2025. We appreciate the Food and Drugs Authority (FDA) Ghana for further issuing a **disclaimer** affirming that **no such clinical trial involving COA-72 has been approved for HIV treatment**, which aligns with COARMLC's position.

#### 2. Background and Research Journey

During the interaction with the committee members, COARMLC's Founder and

CEO, **Mr. Samuel Ato Duncan**, shared the personal and professional journey that has driven the company's research initiatives:

- On **30th November 2005**, Mr. Duncan publicly committed to pursuing a natural cure for HIV.
- This vision led to extensive research in plant-based medicine and the development of key products, including **COA Mixture, COA Plus Mixture, COA-MT Mixture, and COA Capsules**.
- While these products are not intended or approved for HIV treatment, the research laid the foundation for the development of **COA-72**, a new formulation believed — based on preliminary studies to have properties that may fight viral infections and cancers.

### 3. Introducing COA-72: A Call for National Support

At no point during the meeting with the Parliamentary Select Committee did COARMLC claim that COA-72 was undergoing FDA-approved clinical trials. Rather, management took the opportunity to:

- **Introduce COA-72** as a promising formulation based on internal and collaborative research findings.
- **Highlight** the need for further, scientifically rigorous studies.
- **Appeal** for government and institutional support to initiate formal clinical trials, which require significant investment and technical resources.

COARMLC believes that if proven effective through proper clinical trials, COA-72 has the potential to contribute an estimated **\$76.8 billion annually** to Ghana's economy and create thousands of jobs.

### 4. Application to the FDA and the Current Status

To clarify the regulatory engagement:

- In **2019**, COARMLC submitted a formal **application to the FDA** requesting to **initiate clinical trials on COA-72**.
- The FDA acknowledged receipt of this application via a letter dated **29th October 2019** (ref FDA/SMC/CTD/CTA/19/0059) titled:  
***“ACKNOWLEDGEMENT: APPLICATION FOR ANTI HIV/AIDS CLINICAL ON COA-72.”***

- This letter outlined the necessary steps to begin the clinical trial process, including partnerships with accredited research institutions, medical professionals, and adherence to internationally recognised protocols.

**To date, COARMLC has not fully satisfied the FDA’s requirements for approval to commence these clinical trials."**

## **5. Clarifying the Company’s Position**

COARMLC wishes to **categorically state**:

- The company has **never claimed** that FDA approval has been granted for clinical trials on COA-72.
- Pre-clinical and pilot studies including those conducted in Ghana and at reputable institutions outside the country — have shown promising results, including **significant reductions in HIV viral load**, and in some cases, **complete viral clearance** following various modes of administration.
- These preliminary findings are **not substitutes** for formal FDA-approved clinical trials.

## **6. Our Commitment to Scientific and Regulatory Standards**

COARMLC remains steadfast in its commitment to:

- Uphold all regulatory requirements and best practices as outlined by the FDA, WHO, and other international health bodies.
- Collaborate with relevant stakeholders to secure the support and funding necessary to advance COA-72 through formal clinical trials.
- Maintain honest, respectful, and transparent dialogue with the Ghanaian public and the global health community.

## **Conclusion**

We deeply regret any confusion caused by the miscommunication in the media and trust that this statement provides the necessary clarity. COARMLC remains focused on its mission to innovate responsibly in the field of plant-based medicine for the benefit of public health and national development.

**Signed:**  
**Management**